Neurodegeneration research leader arrives
Ray to drive quest for new Alzheimer's disease therapies
Jim Ray, Ph.D., has joined MD Anderson’s Institute for Applied Cancer Science as head of research for the Neurodegeneration Consortium (NDC), a collaboration among MD Anderson, Baylor College of Medicine and the Massachusetts Institute of Technology.
Ray has extensive experience in the pharmaceutical and biotech industries, focusing on Alzheimer’s disease, schizophrenia, Parkinson’s disease, and endocrine and metabolic disorders. Formerly director at Takeda Pharmaceutical’s CNS Research, he’s responsible for coordinating NDC efforts and collaborating with drug discovery scientists at the Institute for Applied Cancer Science to bring innovative therapies to patients with neurodegenerative disease.